CONTEXT:  Report from ASCO 2021 from the MYLUNG Consortium research study in metastatic NSCLC.  The findings based on the results from the first of 5 protocols is a retrospective review of 3,500 mNSCLC patients.  In the context of rapidly changing treatment paradigms for NSCLC the evidence provided showed gaps in genetic testing and slow turn around times leading to delays in initiating treatments for patients | US only data

IMPACT:  Medium

READ TIME:  5 mins

Quality Level Mean [1 – 10]:  8

1. “Dr. Evangelist presented the findings during an oral presentation at ASCO titled, “Biomarker tissue journey among patients with untreated metastatic non-small cell lung cancer (mNSCLC) in The US Oncology Network community practices.”” 

2. “THE WOODLANDS, Texas–(BUSINESS WIRE)–Jun 4, 2021–. Results from the first phase of the broad, collaborative MYLUNG Consortium ™ research study in metastatic non-small cell lung cancer (mNSCLC) were released by The US Oncology Network (The Network), US Oncology Research and Ontada ™ at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.” 

3. ““The pace and development of treatments in non-small cell lung cancer is dramatic,” said Makenzi Evangelist, MD, principal investigator for the MYLUNG Consortium’s Protocol 2 and oncologist with New York Oncology Hematology ( NYOH ), a practice in The Network.” 

4. “Protocol 1, which was just completed, is a retrospective study of more than 3,500 patients with mNSCLC that investigated the following areas: testing rates for ALK, BRAF, EGFR, ROS1, and PD-L1 mutations; use of the full next-generation sequencing panel (NGS); time from NSCLC diagnosis to first-line therapy; turnaround times from biomarker orders to results; and time from NSCLC diagnosis to test results.” 

5. “Part of McKesson Corporation, we partner with life science companies to support science through real-world data and evidence, helping to accelerate drug development and commercialization, connect community oncology providers to educational programs that enable them to practice at the forefront of therapies, and advance precise, evidence-driven patient care through practice technologies in the community setting.” 

Source URL: https://www.galvnews.com/news_ap/business/article_f79b36d5-c91a-585d-b139-e88f2bbda7ac.html